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Insulin resistance is often characterized as the
most critical factor contributing to the devel-
opment of type 2 diabetes. SIRT1 has been
reported to be involved in the processes of glu-
cose metabolism and insulin secretion. How-
ever, whether SIRT1 is directly involved in insu-
lin sensitivity is still largely unknown. Here we
show that SIRT1 is downregulated in insulin-
resistant cells and tissues and that knockdown
or inhibition of SIRT1 induces insulin resistance.
Furthermore, increased expression of SIRT1
improved insulin sensitivity, especially under
insulin-resistant conditions. Similarly, resvera-
trol, a SIRT1 activator, enhanced insulin sen-
sitivity in vitro in a SIRT1-dependent manner
and attenuated high-fat-diet-induced insulin
resistance in vivo at a dose of 2.5 mg/kg/day.
Further studies demonstrated that the effect
of SIRT1 on insulin resistance ismediated by re-
pressing PTP1B transcription at the chromatin
level. Taken together, the finding that SIRT1
improves insulin sensitivity has implications
toward resolving insulin resistance and type 2
diabetes.
INTRODUCTION
Diabetes mellitus, the most common endocrine disorder,
currently affects more than 170 million people worldwide
and will prospectively affect more than 353 million by the
year 2030 (Wild et al., 2004; Yach et al., 2006). Two forms
of diabetes, type 1 and type 2, have been identified. Type
1 diabetes is primarily due to the autoimmune-mediated
destruction of pancreatic islet b cells, resulting in absolute
insulin deficiency. Type 2 diabetes, which more than 90%
of diabetes patients suffer from, is characterized by the re-
sistance of target tissues to insulin stimulation (Wild et al.,
2004). The peptide hormone insulin lowers blood glucose
levels by facilitating glucose uptake, mainly into skeletal
muscle and fat tissue, and by inhibiting endogenous glu-
cose production in the liver (Saltiel and Kahn, 2001). Insu-Celllin resistance occurs when a normal dose of the hormone
is incapable of eliciting thesemetabolic responses (Saltiel,
2001). Development of insulin resistance is a multistep
process with strong genetic and environmental influ-
ences, and the precise pathogenesis and the pathophys-
iological sequence resulting in insulin resistance are still
largely unknown. Currently, alleviating insulin resistance
is still one of the key avenues to treating type 2 diabetes
(Mokdad et al., 2003).
SIRT1 is one of sevenmammalian orthologs of the yeast
protein silent information regulator 2 (Sir2), a conserved
NAD-dependent protein deacetylase that plays a role in
extension of life span and in chromatin remodeling associ-
ated with gene silencing (Blander and Guarente, 2004;
Bordone et al., 2006; Longo and Kennedy, 2006; Rogina
et al., 2002). SIRT1 has also been suggested to be in-
volved in the processes of glucose homeostasis and insu-
lin secretion. Rodgers et al. (2005) showed that SIRT1
controls hepatic glucose metabolism by interacting with
and deacetylating PGC-1a, a key transcriptional coactiva-
tor that controls glucosemetabolism in the liver at the level
of gene transcription. Recently, SIRT1 was shown to be
capable of upregulating insulin secretion in response to
glucose stimulation in pancreatic b cells and thus improv-
ing glucose tolerance in mice (Moynihan et al., 2005).
However, SIRT1 knockout mice exhibit lower blood glu-
cose levels than wild-type mice (Bordone et al., 2006).
Recently, elucidation of the role of SIRT1 in attenuating
adipogenesis in 3T3-L1 adipocytes by repressing PPARg
(Picard et al., 2004) has provided a direction toward
resolving obesity, as well as obesity-related metabolic
diseases including insulin resistance and type 2 diabetes.
Resveratrol, a plant-derived polyphenolic compound, has
been receiving increasing attention as a potent activator of
SIRT1 as evidenced by the findings that resveratrol can
mimic caloric restriction and delay the aging process in
a Sir2-dependent manner (Howitz et al., 2003). More re-
cently, oral administration of resveratrol at a dose of
22.4 mg/kg/day was shown to improve insulin sensitivity
and to slightly reduce the body weight of 1-year-old
mice fed a high-fat diet (Baur et al., 2006). Additionally,
resveratrol at a dose of 400 mg/kg/day has been demon-
strated to prevent diet-induced obesity and alleviate obe-
sity-related insulin resistance, and resveratrol-induced
deacetylation of PGC-1a is mediated by SIRT1 with RNAMetabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 307
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SIRT1 Improves Insulin SensitivityFigure 1. SIRT1 Protein Levels Decrease in Insulin-Resistant Cells and in Muscle of Mice with Impaired Glucose Tolerance
(A) Insulin resistance induced by palmitate in C2C12 myotubes was confirmed by glucose uptake assay. **p < 0.01 versus normal control without
insulin treatment; NS, no significant difference. In this and all other figures, error bars represent SD.
(B) SIRT1 protein levels decreased in insulin-resistant C2C12 myotubes induced by palmitate when examined by western blot. **p < 0.01 versus nor-
mal control.
(C) Insulin resistance induced by glucosamine in HepG2 cells was confirmed by glycogen synthesis assay. **p < 0.01 versus normal control without
insulin treatment; NS: no significant difference.
(D) SIRT1 protein levels decreased in insulin-resistant HepG2 cells induced by glucosamine. **p < 0.01 versus normal control.
(E) Glucose tolerance was impaired after 16 weeks on a high-fat (HF) diet. n = 8; *p < 0.05, **p < 0.01 versus chow-fed group at the same time point.
(F) SIRT1 protein levels decreased in the gastrocnemiusmuscle of mice from (E). *p < 0.05 versus chow-fed group. Quantification was performed with
the results of at least three samples from different mice.interference (RNAi) in C2C12 myotubes or Sirt1/murine
embryonic fibroblast cells (Lagouge et al., 2006). How-
ever, whether SIRT1 has a direct effect on insulin resis-
tance has yet to be elucidated, and whether resveratrol
acts directly or indirectly through SIRT1 is still a subject
of debate (Denu, 2005).
Protein tyrosine phosphatase (PTP) constitutes a family
of phosphatases, including PTP1B, SHP1, SHP2, and
LAR, which act to reverse tyrosine kinase action (Alonso
et al., 2004; Tonks, 2006). As a negative regulator of the in-
sulin signal transduction cascade, PTP1B has been
shown to function as a key insulin receptor phosphatase
(Moller, 2001). PTP1B-deficient mice are more sensitive
to insulin, have improved glycemic control, and are more
resistant to diet-induced obesity than wild-type mice
(Elchebly et al., 1999). Diabetic mice treated intraperitone-
ally with PTP1B antisense oligonucleotides have lower
PTP1B protein levels in liver, leading to decreases in fat,
plasma insulin, and blood glucose levels (Zinker et al.,
2002). These findings indicate that inhibition or down-
regulation of PTP1B is an effective strategy for improving
insulin sensitivity.
In this study, we directly investigated the effect of SIRT1
on insulin sensitivity under normal versus insulin-resistant
conditions. The role of resveratrol was studied both in vitro
and in vivo. Our data reveal that SIRT1 and resveratrol im-
prove insulin sensitivity by repressing PTP1B transcription308 Cell Metabolism 6, 307–319, October 2007 ª2007 Elsevierat the chromatin level and that resveratrol is effective
in vitro and in vivo at a much lower concentration than
reported previously, in a SIRT1-dependent manner. Our
findings suggest a potential therapeutic approach for pre-
venting or treating insulin resistance and type 2 diabetes.
RESULTS
SIRT1 Protein Level Decreases under
Insulin-Resistant Conditions
To investigate whether SIRT1 is involved in insulin resis-
tance, we compared SIRT1 protein levels under normal
and insulin-resistant conditions. As shown in Figure 1A, in-
sulin-stimulated glucose uptake was blocked by palmitate
in C2C12 myotubes. Similarly, glycogen synthesis was
also blocked by glucosamine in HepG2 cells (Figure 1C).
These results show that palmitate and glucosamine in-
duce insulin resistance in C2C12 myotubes and HepG2
cells, respectively. As expected, SIRT1 protein levels de-
creased significantly under insulin-resistant conditions in
both C2C12 myotubes and HepG2 cells (Figures 1B and
1D). To further investigate this decline in vivo, we mea-
sured SIRT1 protein levels in insulin-resistant mice. Ac-
cording to the results of a glucose tolerance test, 16 weeks
of high-fat diet (HFD) feeding significantly impaired glu-
cose tolerance (Figure 1E). As expected, SIRT1 protein
levels were also decreased in the gastrocnemius muscleInc.
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SIRT1 Improves Insulin SensitivityFigure 2. Knockdown or Inhibition of
SIRT1 Induces Insulin Resistance
(A) HepG2 cells were infected with lentivirus
expressing both EGFP and luciferase (Luc)
RNAi or SIRT1 RNAi as evidenced by represen-
tative light-field or fluorescence photos.
HepG2 cells without lentivirus infection were
used as control.
(B) Lentivirus-mediated SIRT1 knockdown in
HepG2 cells was confirmed by western blot.
Luciferase RNAi was used as a control.
(C) Knockdown of SIRT1 impaired insulin
receptor (InsR) phosphorylation stimulated by
insulin in HepG2 cells.
(D and E) Knockdown of SIRT1 by RNAi (D) or
inhibition of SIRT1 by sirtinol (E) blocked insu-
lin-stimulated glycogen synthesis in HepG2
cells. **p < 0.01 versus respective control with-
out insulin treatment; NS: no significant differ-
ence.of mice fed a HFD as compared to the chow-fed group
(Figure 1F). These results suggest that SIRT1 is involved
in insulin resistance.
Knockdown or Inhibition of SIRT1 Induces
Insulin Resistance
A reduction in SIRT1 protein levels under insulin-resistant
conditions raises the possibility that knockdown or inhibi-
tion of SIRT1 might induce insulin resistance. To address
this possibility, lentiviruses expressing both enhanced
green fluorescent protein (EGFP) and SIRT1 RNAi or lucif-
erase RNAi were packaged, and HepG2 cells were highly
infected as evidenced by expression of EGFP (Figure 2A).
As shown in Figure 2B, the endogenous SIRT1 protein
level was effectively reduced by RNAi. At the same time,
insulin-stimulated tyrosine phosphorylation of insulin re-
ceptor (InsR) was greatly impaired in the SIRT1 knock-
down cells (Figure 2C). Similarly, insulin-stimulated glyco-
gen synthesis was also impaired in the SIRT1 knockdown
cells (Figure 2D). When HepG2 cells were treated with the
SIRT1 inhibitor sirtinol (Grozinger et al., 2001), glycogen
synthesis in response to insulin stimulation was also
significantly impaired (Figure 2E). Taken together, these
data show that SIRT1 is essential for insulin signaling
and that knockdown or inhibition of SIRT1 is sufficient to
induce insulin resistance.
Increased Expression of SIRT1 Improves
Insulin Sensitivity
The reduction of SIRT1 protein levels under insulin-
resistant conditions, as well as the induction of insulin
resistance in SIRT1-downregulated cells, leads to a postu-
lation that increased dosage of SIRT1 may attenuate insu-
lin resistance. Thus, we increased SIRT1 expression in
C2C12 myotubes by employing herpes simplex virusCell(HSV) infection. As shown in Figure 3D, SIRT1 protein
levels increased remarkably in a dose-dependent manner
in C2C12 myotubes infected with the recombinant HSV
encoding Sirt1. We next determined the effect of in-
creased SIRT1 dosage on glucose uptake and insulin sig-
naling. As shown in Figure 3A, glucose uptake was signif-
icantly increased upon insulin stimulation in the presence
or absence of HSV-SIRT1 virus infection, and no statistical
difference was observed between helper virus-infected
cells and HSV-SIRT1 virus-infected cells. Basal glucose
uptake was not significantly affected by increased expres-
sion of SIRT1. However, under insulin-resistant conditions
induced by palmitate, SIRT1 significantly enhanced insu-
lin-stimulated glucose uptake and glycogen synthase
activity upregulation (Figures 3B and 3C). Stimulation of
C2C12 myotubes with insulin enhanced the phosphoryla-
tion of InsR at Tyr1146, as well as Akt at Thr308 and
Ser473, PDK1 at Ser241, and GSK-3b at Ser9 (Figure 3D).
Increased expression of SIRT1 under normal conditions
did not affect insulin-stimulated phosphorylation of these
downstream proteins (Figure 3D). When insulin resistance
was induced in C2C12myotubes by palmitate, the insulin-
stimulated phosphorylation of these downstream proteins
was impaired remarkably (Figure 3E). This impairment was
significantly rescued by SIRT1, since the improvements in
insulin-stimulated phosphorylation of the downstream
proteins were observed in SIRT1-overexpressing cells
(Figure 3E). (For quantitation of the results shown in
Figure 3E, see Figure S1 in the Supplemental Data avail-
able with this article online.) Furthermore, SIRT1 improved
the response to insulin under insulin-resistant conditions
when cells were stimulated with different doses of insulin.
The deacetylase activity of SIRT1 is required for its effect
on improving insulin sensitivity, since the SIRT1-363Ymu-
tant, which lacks deacetylase activity, failed to improveMetabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 309
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SIRT1 Improves Insulin SensitivityFigure 3. Increased Expression of SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions but Not under Normal
Conditions
(A) Increased expression of SIRT1 with herpes simplex virus (HSV) had no significant effect on basal or insulin-stimulated glucose uptake in C2C12
myotubes under normal conditions. Helper virus used for recombinant HSV packagingwas used as a control. **p < 0.01 versus cells only infected with
helper virus and without insulin treatment. moi, multiplicity of infection.
(B and C) Increased expression of SIRT1 with HSV improved insulin-stimulated glucose uptake and glycogen synthase activity upregulation in C2C12
myotubes under insulin-resistant conditions induced by palmitate. *p < 0.05, **p < 0.01 versus cells only infected with helper virus and with insulin
treatment. G6P, glucose-6-phosphate.
(D) Increased expression of SIRT1 had no significant effect on insulin signaling, including the phosphorylation of InsR, Akt, GSK-3b, and PDK1, in
C2C12 myotubes under normal conditions. Protein levels were analyzed by western blot.
(E) Increased expression of SIRT1 significantly enhanced insulin signaling, including the phosphorylation of InsR, Akt, GSK-3b, and PDK1, in C2C12
myotubes under insulin-resistant conditions induced by palmitate.
(F) The response to different doses of insulin was improved by SIRT1 in C2C12 myotubes under insulin-resistant conditions induced by palmitate.
(G) The SIRT1-363Y mutant failed to improve insulin signaling in C2C12 myotubes under insulin-resistant conditions induced by palmitate.310 Cell Metabolism 6, 307–319, October 2007 ª2007 Elsevier Inc.
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SIRT1 Improves Insulin Sensitivityinsulin sensitivity (Figure 3G). These data clearly indicate
that increased expression of SIRT1 improves glucose
uptake and insulin signaling, especially under insulin-
resistant conditions.
Resveratrol Improves Insulin Sensitivity In Vitro
in a SIRT1-Dependent Manner
To further ascertain the positive effect of SIRT1 on insulin
sensitivity, we applied the SIRT1 activator resveratrol (Ho-
witz et al., 2003) at a wide range of concentrations. As
shown in Figure 4A, glucose uptake in C2C12 myotubes
stimulated by insulin was significantly enhanced by re-
sveratrol under normal conditions. Correspondingly, re-
sveratrol application also enhanced the insulin-evoked
phosphorylation of InsR, Akt, PDK1, and GSK-3b under
normal conditions (Figure 4C). Resveratrol enhanced
insulin-stimulated glucose uptake under insulin-resistant
conditions as well (Figure 4B). The effect of resveratrol
on insulin sensitivity under insulin-resistant conditions
was further confirmed by elevated phosphorylation of
these downstream proteins in insulin signaling (Figure 4D).
Interestingly, besides acting as a SIRT1 activator, resver-
atrol upregulated SIRT1 protein levels, especially under in-
sulin-resistant conditions (Figure 4D).
To investigate whether resveratrol has a similar effect on
other cells responding to insulin, primary cultured rat
adipocytes and HepG2 cells were also examined. As we
expected, the application of resveratrol improved insu-
lin-stimulated glucose uptake significantly in primary rat
adipocytes (Figure 4E). Notably, basal glucose uptake
was also enhanced by resveratrol treatment. Similarly, re-
sveratrol enhanced basal glycogen synthesis in HepG2
cells (Figure 4F). These data demonstrate that resveratrol
can enhance insulin sensitivity in different types of insulin-
responsive cells.
To address whether resveratrol functions in a SIRT1-
dependent manner, we infected HepG2 cells with lentivirus
expressing SIRT1 RNAi or luciferase RNAi as a control. Gly-
cogen synthesis was stimulated significantly by all three
testedconcentrationsof resveratrol inHepG2cells express-
ing luciferase RNAi, but resveratrol-stimulated glycogen
synthesis was markedly diminished in the SIRT1 knock-
down cells (Figure 4F). These findings clearly indicate that
resveratrol functions in a SIRT1-dependent manner.
Resveratrol Improves Insulin Sensitivity In Vivo
We next investigated whether resveratrol improves insulin
sensitivity in vivo as well as in vitro. Mice fed a HFD
exhibited impaired glucose tolerance, and resveratrol
treatment significantly improved glucose tolerance in
HFD-fed mice, with glucose disposal curves comparable
to those of chow-fed mice (Figures 5A and 5B). The ability
of insulin to decrease blood glucose concentration was
also markedly reduced in HFD-fed mice compared with
chow-fed mice, and resveratrol administration signifi-
cantly improved the response to insulin in HFD-fed mice
(Figures 5C and 5D). Furthermore, we found that there
was a dramatic increase in fasting plasma insulin levels
in HFD-fed mice in comparison to chow-fed mice, and re-Cell Msveratrol administration attenuated the increase in plasma
insulin levels significantly (Figure 5E). In addition, the in-
creased total cholesterol and low-density lipoprotein
levels induced by HFD were partially restored by resvera-
trol administration (Figures 5F and 5G), while no significant
changes were observed in the levels of triglycerides and
high-density lipoprotein by resveratrol administration
(data not shown). Collectively, these data demonstrate
that resveratrol improves insulin sensitivity in HFD-fed
mice via the findings that resveratrol-treated mice were
better able to control plasma glucose levels using nearly
normal levels of insulin.
The difference between our applied dose of resveratrol
and the doses previously reported (Baur et al., 2006;
Lagouge et al., 2006) drove us to investigate the exact
levels of resveratrol in vivo. Plasma, liver, and muscle
samples from HFD-fed mice receiving resveratrol at
a dose of 2.5 mg/kg/day were analyzed by liquid chroma-
tography/tandem mass spectrometry (LC-MS/MS) as
shown in Figure S2. The levels of resveratrol in the plasma,
liver, and muscle samples from resveratrol-treated mice
were 0.45 ± 0.39 nmol/l, 5.59 ± 3.45 nmol/kg, and 0.72 ±
0.50 nmol/kg, respectively (Figure 5H). The detected
levels of resveratrol in vivo were quite close to the concen-
trations that we applied in vitro. These results demon-
strated the resveratrol concentration range used in vitro
in this study was reasonable.
In addition, we administered the SIRT1 inhibitor nicotin-
amide to mice fed a chow diet for 8 weeks. Treatment with
nicotinamide significantly increased body weight, fat
mass, energy intake, and fasting blood glucose levels in
thesemice (Figures 5I–5L). Although impaired glucose tol-
erance was not observed in nicotinamide-treated mice
(data not shown), the increased fat mass and fasting blood
glucose levels induced by nicotinamide provide further ev-
idence for the role of SIRT1 in regulating insulin sensitivity.
SIRT1 and Resveratrol Improve Insulin Sensitivity
by Repressing PTP1B
To examine the underlying mechanism responsible for
SIRT1-mediated improvement of insulin sensitivity, we
tested several pharmaceutical targets affecting insulin
sensitivity. PTP1B, a well-known negative regulator of
the insulin signaling pathway (Elchebly et al., 1999; Moller,
2001), was found to be an effective target downregulated
by SIRT1 or resveratrol. Under normal conditions, PTP1B
protein levels were decreased slightly by SIRT1 (Figure 6A,
left panel), while under insulin-resistant conditions, PTP1B
protein level decreased strikingly in the SIRT1-overex-
pressing cells (Figure 6A, right panel). The deacetylase ac-
tivity of SIRT1 was required for its downregulatory effect
on PTP1B protein levels (Figure 6B). Moreover, we found
that PTP1B mRNA levels were decreased significantly
by increased expression of SIRT1 under insulin-resistant
conditions (Figure 6C). Resveratrol decreased PTP1B pro-
tein and mRNA levels remarkably under both normal and
insulin-resistant conditions (Figures 6D and 6E). These re-
sults suggest that the effects of SIRT1 and resveratrol on
insulin sensitivity might be due to PTP1B repression.etabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 311
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SIRT1 Improves Insulin SensitivityFigure 4. Resveratrol Enhances Insulin Sensitivity under Both Normal and Insulin-Resistant Conditions
(A and B) Resveratrol enhanced insulin-stimulated glucose uptake in C2C12 myotubes under both normal and insulin-resistant conditions. **p < 0.01
versus cells without any treatment; #p < 0.05, ##p < 0.01 versus insulin-treated cells in the absence of resveratrol.
(C and D) Resveratrol improved insulin signaling, including the phosphorylation of InsR, Akt, GSK-3b, and PDK1, in C2C12 myotubes under both nor-
mal and insulin-resistant conditions. Protein levels were analyzed by western blot. SIRT1 was upregulated by resveratrol under insulin-resistant con-
ditions.
(E) Resveratrol enhanced glucose uptake in primary-cultured rat adipocytes. **p < 0.01 versus cells without any treatment; ##p < 0.01 versus insulin-
treated cells in the absence of resveratrol.
(F) Resveratrol enhanced glycogen synthesis in HepG2 cells, and this effect required SIRT1. *p < 0.05, **p < 0.01 versus cells expressing luciferase
(Luc) RNAi without insulin and resveratrol treatments; ##p < 0.01 versus cells expressing Luc RNAi treated with the same concentration of resveratrol.To further confirm the above in vitro results, we explored
the relationship between SIRT1 and PTP1B in vivo. A pre-
vious report indicated that SIRT1 protein levels are in-312 Cell Metabolism 6, 307–319, October 2007 ª2007 Elseviercreased in the fasting state in mouse liver (Rodgers
et al., 2005). Thus, we employed this strategy to upregu-
late SIRT1 protein level in vivo. As shown in Figure 6F,Inc.
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SIRT1 Improves Insulin SensitivityFigure 5. Resveratrol Ameliorates High-Fat-Diet-Induced Glucose Intolerance and Insulin Resistance, and Nicotinamide
Increases Body Weight and Fasting Blood Glucose Levels in Chow-Fed Mice
(A) Resveratrol (Res) improved glucose tolerance in mice fed a high-fat (HF) diet as determined by glucose tolerance test (n = 8).
(B) Resveratrol significantly reduced the area under the curve (AUC) of the glucose tolerance test in (A). **p < 0.01 versus chow; ##p < 0.01 versus HF.
(C) Resveratrol improved insulin sensitivity in HF-fed mice as determined by insulin tolerance test (n = 8).
(D) Resveratrol significantly reduced the AUC of the insulin tolerance test in (C). **p < 0.01 versus chow; ##p < 0.01 versus HF.
(E–G) Plasma insulin (E), total cholesterol (TC, [F]), and low-density lipoprotein (LDL, [G]) in HF-fedmice was attenuated by resveratrol treatment. **p <
0.01 versus chow; ##p < 0.01 versus HF.
(H) Levels of resveratrol in plasma, liver, and muscle of resveratrol-treated mice analyzed by LC-MS/MS (n = 6). Resveratrol was extracted and mea-
sured after animals were administered resveratrol at 2.5 mg/kg/day for 6 weeks.
(I–L) Nicotinamide (NAM) significantly increased body weight (I), fat mass (J), energy intake (K), and fasting blood glucose levels (L) in chow-fed mice.
n = 8; *p < 0.05, **p < 0.01 versus chow.SIRT1 protein levels in liver were increased significantly by
fasting and returned to normal chow-fed levels upon
refeeding. At the same time, PTP1B protein levels were
decreased remarkably in the fasting state and were re-
stored by refeeding (Figures 6F and 6G). PTP1B protein
levels were slightly but significantly increased in palmi-
tate-treated C2C12 myotubes (Figure S3). Furthermore,
SIRT1 protein levels were significantly decreased in gas-
trocnemius muscle of HFD-fed mice, and PTP1B levels in-
creased simultaneously (Figures 6H and 6I). Resveratrol
treatment to activate SIRT1 restored PTP1B to levels
comparable to the chow-fed group. These data suggest
that SIRT1, as well as resveratrol, may negatively regulate
PTP1B in vivo.
To confirm that SIRT1 improves insulin sensitivity by
repression of PTP1B, we next determined the effect of in-
creased PTP1B expression on SIRT1-enhanced insulinCell Msensitivity by upregulating expression of SIRT1 and
PTP1B in C2C12 myotubes via infection with HSV encod-
ing Sirt1 and PTP1B, respectively. Western blots showed
that the infected cells expressed PTP1B and/or SIRT1
strongly (Figure 7A). As expected, increased expression
of SIRT1 improved insulin-stimulated InsR phosphoryla-
tion under insulin-resistant conditions, and this improve-
ment was largely prevented by increased expression of
PTP1B (Figure 7A). Similarly, the improved insulin-
stimulated glucose uptake by SIRT1 was largely impaired
by increased expression of PTP1B (Figure 7B). These data
demonstrate that improvement of insulin sensitivity by
SIRT1 is dependent on PTP1B repression. Furthermore,
the PTP1B inhibitor vanadate reversed the effect of
SIRT1 RNAi on insulin signaling (Figure 7C). Similarly,
knockdown of PTP1B by RNAi also reversed the effect
of SIRT1 RNAi on insulin signaling (Figures 7D and 7E).etabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 313
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SIRT1 Improves Insulin SensitivityFigure 6. SIRT1 and Resveratrol Downregulate PTP1B at Both the Protein and the mRNA Level
(A) Increased expression of SIRT1 repressed PTP1B protein levels in insulin-treated C2C12 myotubes under insulin-resistant conditions induced by
palmitate. Protein levels were analyzed by western blot. moi, multiplicity of infection.
(B) The SIRT1-363Y mutant failed to repress PTP1B protein levels in insulin-treated C2C12 myotubes under insulin-resistant conditions induced by
palmitate.
(C) Increased expression of SIRT1 downregulated PTP1BmRNA levels in insulin-treated C2C12 myotubes under insulin-resistant conditions. PTP1B
mRNA levels were analyzed by RT-PCR. **p < 0.01 versus insulin-treated cells in the absence of resveratrol.
(D and E) Resveratrol (Res) treatment decreased PTP1B protein levels (D) and mRNA levels (E) in insulin-treated C2C12 myotubes. PTP1B mRNA
levels were analyzed by RT-PCR. *p < 0.05, **p < 0.01 versus insulin-treated cells in the absence of resveratrol.
(F) SIRT1 protein levels were negatively correlated with PTP1B protein levels in vivo. Liver lysates frommice fed ad libitum with chow, fasted for 24 hr,
or fasted for 24 hr and refed for 24 hr were analyzed by western blot (n = 6).
(G) Quantification of SIRT1 and PTP1B protein levels corresponding to (F). **p < 0.01 versus chow or refed group.
(H) SIRT1 protein levels and activity were negatively correlated with PTP1B protein levels in gastrocnemius muscle of HF-fed mice with or without
resveratrol treatment. Protein levels were analyzed by western blot.
(I) Quantification of PTP1B and SIRT1 protein levels corresponding to (H). *p < 0.05 versus chow; ##p < 0.01 versus HF.These results further confirm that the effect of SIRT1 on in-
sulin signaling is mediated by PTP1B.
To determine how PTP1B is regulated by SIRT1, the in-
tracellular localization of SIRT1 and PTP1B was detected
by immunofluorescence (Figure 7F). PTP1B and SIRT1
were not colocalized, suggesting that SIRT1 might regu-
late PTP1B at the transcriptional level. A series of reporter
constructs containing different lengths of PTP1B pro-314 Cell Metabolism 6, 307–319, October 2007 ª2007 Elseviermoter were applied, and SIRT1 failed to activate the
PTP1B promoter (Figure 7H). Deacetylation of histone
H3 by SIRT1 was observed in C2C12 myotubes (Fig-
ure 7G), providing the possibility that PTP1B transcription
is regulated at the chromatin level, since deacetylation of
histone usually leads to the inhibition of gene transcrip-
tion. A chromatin immunoprecipitation (ChIP) assay
showed that SIRT1 decreased acetylated histone H3Inc.
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SIRT1 Improves Insulin SensitivityFigure 7. The Effect of SIRT1 on Insulin
Signaling Is Mediated by PTP1B
(A) SIRT1’s ability to improve insulin-stimulated
InsR phosphorylation in C2C12 cells under in-
sulin-resistant conditions induced by palmitate
was impaired by increased PTP1B protein
levels. Protein levels were analyzed by western
blot.
(B) SIRT1’s ability to improve insulin-
stimulated glucose uptake in C2C12 cells
under insulin-resistant conditions was im-
paired by increased PTP1B protein levels.
**p < 0.01 versus control virus-infected cells;
##p < 0.01 versus only SIRT1-overexpressing
cells.
(C) The PTP1B inhibitor vanadate reversed the
effect of SIRT1 RNAi on insulin-stimulated tyro-
sine phosphorylation of InsR.
(D) PTP1B RNAi also reversed the effect of
SIRT1 RNAi on insulin-stimulated phosphory-
lation of InsR.
(E) Lentivirus-mediated PTP1B RNAi in HepG2
cells was confirmed by western blot. Lucifer-
ase RNAi was used as a control.
(F) Intracellular localization of SIRT1 and
PTP1B was detected by immunofluorescence.
Nuclei were stained with DAPI.
(G) SIRT1 decreased the acetylation level of
histone H3 in C2C12 cells under insulin-
resistant conditions induced by palmitate.
(H) SIRT1 failed to activate the PTP1B pro-
moter. A series of reporter constructs contain-
ing different lengths of PTP1B promoter were
used for luciferase assay.
(I) Increased expression of SIRT1 decreased
the binding of acetylated histone H3 to the
PTP1B promoter region. ChIP assay was per-
formed for two PTP1B genomic DNA frag-
ments near the start site.binding to the PTP1B promoter region (Figure 7I). These
data demonstrate that SIRT1 represses PTP1B transcrip-
tion at the chromatin level.
DISCUSSION
Recently, it has been demonstrated that resveratrol im-
proves insulin sensitivity in a diet-induced obesity model
(Baur et al., 2006; Lagouge et al., 2006); these studies
raised the possibility that SIRT1 might be involved in reg-
ulation of insulin sensitivity. However, evidence for direct
SIRT1 association with insulin sensitivity was still not avail-
able. In the present study, we provide some evidence that
SIRT1 is directly involved in the regulation of insulin sensi-
tivity. First, SIRT1 protein levels were markedly decreased
in insulin-resistant cells (Figures 1B and 1D). Second,
there was a reduction in SIRT1 protein levels in the gas-
trocnemius muscle of mice with impaired glucose toler-
ance compared to mice with normal glucose toleranceCell(Figure 1F). Such a decrease in epididymal fat tissue in
a diet-induced obesity model was also reported recently
in another study (Qiao and Shao, 2006). Third, knockdown
or inhibition of SIRT1 impaired InsR phosphorylation and
glycogen synthesis in response to insulin stimulation (Fig-
ures 2C–2E). However, in contrast to our findings, SIRT1
knockout mice exhibit better performance in maintaining
systemic glucose homeostasis as compared to wild-
type mice (Bordone et al., 2006). The precise mechanism
responsible for such a difference observed in vivo and
in vitro remains to be elucidated in the future. It is worth
noting that only a small percentage of SIRT1 null mice
are viable; most die during the immediate postnatal
period. The viable mice exhibit growth retardation and de-
fects in development of the eye, lung, pancreas, and heart,
and both sexes are sterile (Cheng et al., 2003; McBurney
et al., 2003). Therefore, it is reasonable to propose that
the developmental defects in SIRT1-deficient mice may
lead to abnormalities in physiological processes such asMetabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 315
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seem to be a useful model for studying the precise role
of SIRT1 in glucose metabolism in vivo. Importantly, we
also found that increased expression of SIRT1 can atten-
uate insulin resistance (Figures 3B, 3C, and 3E) and that
this effect is dependent on its deacetylase activity
(Figure 3G). It has been reported that pancreatic b cell-
specific SIRT1-transgenic mice show improved glucose
tolerance as a result of enhanced glucose-stimulated in-
sulin secretion (Moynihan et al., 2005). Here, we showed
that SIRT1 can directly improve insulin sensitivity by
stimulating insulin signal transduction and that resveratrol
improves HFD-induced insulin resistance and hyperinsuli-
nemia. Therefore, other tissue-specific SIRT1-transgenic
mice should be established in the future to investigate
the in vivo function of SIRT1 in regulation of insulin sensi-
tivity.
In addition to SIRT1, we found that resveratrol was also
capable of improving insulin sensitivity in vitro. Moreover,
resveratrol was observed to improve insulin sensitivity in
mice with HFD-induced insulin resistance (Figures 5A–
5E). This role of resveratrol in regulation of insulin sensitiv-
ity was consistent with recent reports (Baur et al., 2006;
Lagouge et al., 2006). Notably, the dose of resveratrol ap-
plied in our study was 2.5 mg/kg/day, which was much
lower than the doses of 22.4 or 400 mg/kg/day used in
the above studies. To ascertain an effective concentration
of resveratrol for improving insulin sensitivity, we utilized
LC-MS/MS to determine resveratrol concentrations in
animal tissues. The level of resveratrol in the plasma of re-
sveratrol-treated mice was 0.11 ± 0.09 ng/ml (0.45 ± 0.39
nM), which was rather low compared to the 10–120 ng/ml
concentration in resveratrol-treated mice administered
a dose of 200 or 400 mg/kg/day (Lagouge et al., 2006).
In addition to plasma, resveratrol was also detected in liver
and muscle tissues, while it was difficult to detect in white
adipose tissue (data not shown), suggesting that liver and
muscle might be the major glucose-metabolizing tissues
responding to resveratrol in vivo. Because several studies
have shown that resveratrol is more effective in vivo than
in cell culture models (Wenzel and Somoza, 2005), we se-
lected several concentrations of resveratrol (0.01, 0.1, and
1.0 mM) close to in vivo concentrations to treat cultured
cells. A previous study reported that resveratrol at con-
centrations of 25–50 mM administered over a short dura-
tion (30 min) improved phosphorylation of AMPK, leading
to a potential increase in insulin sensitivity, but that resver-
atrol failed to improved phosphorylation of AMPK at
12.5 mM (Baur et al., 2006). Here, we also observed that
phosphorylation of AMPK was induced by resveratrol at
50 mM, and, as expected, low concentrations of resvera-
trol from 0.01–1 mM used to improve insulin sensitivity
in vitro failed to induce AMPK phosphorylation (data not
shown). These results suggest that resveratrol may func-
tion at different concentration ranges with different mech-
anisms. When the resveratrol concentration is higher than
10 mMover a 24 hr duration, it produces toxic effects in dif-
ferentiated C2C12 cells (data not shown). Consistent with
this finding, a recent investigation has suggested that high316 Cell Metabolism 6, 307–319, October 2007 ª2007 Elsevieconcentrations of resveratrol (100 mM) over a 24 hr dura-
tion can induce cell apoptosis (Hambrock et al., 2007).
Moreover, it has been found that high concentrations of
resveratrol (100 mM) over a short treatment duration
(10–30 min) inhibit insulin response through a SIRT1-
independent pathway (Zhang, 2006). It seems that, at
low concentrations, resveratrol exhibits biological func-
tions in a SIRT1-dependent manner, whereas at high con-
centrations, it probably does so via a SIRT1-independent
pathway. However, the effect of 50 mM resveratrol over
a 24 hr duration has also been shown to be SIRT1 depen-
dent (Lagouge et al., 2006). Therefore, the precise mech-
anisms for the functions of resveratrol remain to be
elucidated. However, low effective concentrations of
resveratrol in insulin sensitivity are of great therapeutic
importance since lower concentrations mean greater
biological safety and lower pharmaceutical cost.
SIRT1 is mainly linked to negative regulation of gene
expression as a cofactor through protein deacetylation
(Vaziri et al., 2001). In the present study, we found that
SIRT1 can repress PTP1B at both the protein and the
mRNA level. It is well demonstrated that decreased
PTP1B results in better responses to insulin stimulation
(Elchebly et al., 1999; Zinker et al., 2002). Moreover, in-
creased expression of PTP1B counteracted SIRT1-medi-
ated improved glucose uptake and InsR phosphorylation
in response to insulin stimulation (Figures 7A and 7B).
The reduction of PTP1B by SIRT1 should contribute, at
least in part, to the enhancement of insulin sensitivity by
SIRT1. Notably, PTP1B protein levels were decreased
by increasing levels of SIRT1 in liver of fasted mice
(Figure 6F). This finding raises the possibility that SIRT1
may also negatively regulate PTP1B in vivo, although
this needs to be verified in the future. Consistent with
our findings, a previous study also showed that PTP1B
protein levels are decreased in liver of fasted mice (Gu
et al., 2003); however, the mechanism involved was not
fully elucidated. Our data suggest that the decrease in liver
PTP1B protein levels in the fasting state is probably due to
the repressive effect of SIRT1 on PTP1B. Although resver-
atrol has been reported to activate phosphatase SHP2
(Haider et al., 2005) as well as SIRT1, resveratrol also re-
pressed PTP1B both in vitro and in vivo (Figures 6D, 6E,
6H, and 6I), indicating that resveratrol has a positive effect
on insulin sensitivity. It has been demonstrated that SIRT1
can deacetylate histone H3 (Vaquero et al., 2004). Here,
we observed similar results in C2C12 myotubes and dem-
onstrated that SIRT1 represses PTP1B transcription at the
chromatin level. In addition, caloric restriction is consid-
ered an effective dietary intervention for increasing insulin
sensitivity (Barzilai et al., 1998; Fontana et al., 2004).
SIRT1 protein levels are increased in calorie-restricted
animals (Howitz et al., 2003). Thus, SIRT1-dependent
repression of PTP1Bmight be involved in improved insulin
sensitivity by caloric restriction.
In conclusion, by repressing PTP1B, SIRT1 improves
insulin sensitivity under insulin-resistant conditions. Simi-
larly, resveratrol, a potent activator of SIRT1, is also capa-
ble of enhancing insulin sensitivity both in vitro and in vivor Inc.
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including resveratrol that enhance SIRT1 function and/or
expression might provide a valuable new strategy for
treating insulin resistance and type 2 diabetes.
EXPERIMENTAL PROCEDURES
Preparation of Recombinant Lentivirus and Herpes
Simplex Virus
The H1 promoter was amplified by PCR from pSilencer 3.1-H1 hygro
(Ambion) and inserted into XbaI and XhoI sites of the pLentiLox 3.7.
The oligonucleotides and primers used in this study are described in
the Supplemental Experimental Procedures. The oligonucleotides for
RNAi were annealed and ligated into the BamHI and XhoI sites of
pLentiLox 3.7 with the H1 promoter. Recombinant lentiviruses were
produced in 293T cells by cotransfecting the construct containing lu-
ciferase RNAi, SIRT1 RNAi, or PTP1B RNAi with the packaging vectors
D8.9 and VSVG and were subsequently concentrated and titered as
described previously (Abbas-Terki et al., 2002). pBabepuro-hSIRT1
and pBabepuro-hSIRT1-363Y were a kind gift from W. Gu (Luo et al.,
2001). The Sirt1 and Sirt1-363Y genes were obtained from pBabe-
puro-hSIRT1 and pBabepuro-hSIRT1-363Y and subcloned into recon-
structed pHSVPrPUC-myc vector at the BamHI site. The PTP1B cDNA
was amplified by RT-PCR from mouse muscle tissue and subcloned
into MluI and SalI sites in pHSVPrPUC-myc vector. The recombinant
HSV-SIRT1 and HSV-PTP1B virus particles were prepared, amplified,
and titered as described previously (Wang et al., 2005).
Cell Culture and Treatments
C2C12myoblasts were maintained in DMEMwith 10%FBS and differ-
entiated in DMEMwith 2% horse serum after reaching confluence. Af-
ter 4 days, the C2C12 cells were differentiated into myotubes and
treated with resveratrol or infected with recombinant HSV for 24 hr at
the indicated concentrations or titers. Myotubes were then incubated
for 18 hr in DMEM containing 2% BSA and 10% FBS in the absence or
presence of 0.75 mM palmitate to induce insulin resistance. Subse-
quently, the treated cells were stimulated with 100 nM insulin for
20min, and cells were then harvested for RT-PCR,western blot, or glu-
cose uptake assay. HepG2 cells were maintained in DMEM with
25 mM glucose and 10% FBS. To induce insulin resistance, HepG2
cells were treated with 18 mM glucosamine for 18 hr in DMEM with
5 mM glucose. For lentivirus infection, HepG2 cells were treated with
6 mg/ml polybrene overnight and then infected with the indicated len-
tivirus for at least 3 days. After infection with lentivirus expressing
SIRT1 RNAi, cells were treated with resveratrol at the indicated con-
centrations for 24 hr. To inhibit SIRT1, HepG2 cells were pretreated
with 50 mM sirtinol (Sigma) for 12 hr. To inhibit PTP1B, cells were
treated with 100 mM vanadate for 30 min. For western blot, cells
were subsequently treated with 100 nM insulin for 20 min. Rat adipo-
cytes were isolated from the epididymal fat pads of 150–170 g
Sprague-Dawley rats (SLACCAS) as described previously (Wu et al.,
2003). The prepared adipocytes were cultured in DMEM containing
2% insulin-free BSA (Sigma), 25 mM HEPES, and 0.5% FBS. Resver-
atrol was applied to rat adipocytes at the indicated concentrations for
10 hr, and the cells were then treated with 100 nM insulin for 20 min
before glucose uptake assay.
Glucose Uptake Assay
Glucose uptake was determined using a method described previously
(Jove et al., 2006). In brief, cells were incubated for 20 min at 37C in
the absence or presence of 100 nM insulin in Krebs-Ringer phosphate
buffer (128 mM NaCl, 4.7 mM KCl, 5 mM NaH2PO4, 5 mM Na2HPO4,
1.25mMMgSO4, 1.25mMCaCl2 [pH 7.4]). [
3H]2-deoxyglucose (Amer-
sham) and 2-deoxyglucose were then added to a final concentration of
1 mCi/ml and 0.1 mM, respectively, and incubated for 5 min. After
washing four times with ice-cold PBS, the cells were lysed with
0.5MNaOH for 30min. Radiolabeled glucose in lysateswasmeasuredCell Min a high-flashpoint scintillation cocktail (PerkinElmer) using a liquid
scintillation counter.
Glycogen Synthesis Assay and Measurement of Glycogen
Synthase Activity
Glycogen synthesis was determined using a modified method
described previously (Sakai et al., 2002). HepG2 cells cultured in
24-well plates were treated with 100 nM insulin and 1 mCi/ml
[3H]glucose in DMEM with 5 mM glucose for 3 hr and then harvested
for glycogen synthesis assay. Cells in each well were lysed in 200 ml
30% KOH with 5 mg/ml glycogen at 60C for 30 min. The cell lysates
were collected, and glycogen was precipitated overnight at 20C
by adding 1 ml of ethanol. Glycogen was separated by centrifugation
at 5000 3 g for 10 min, and the pellets were washed twice with 75%
ice-cold ethanol. Finally, the pellets were solubilized in 200 ml of
0.1 M HCl and measured by a liquid scintillation counter by adding
0.7 ml of high-flashpoint scintillation cocktail. Glycogen synthase ac-
tivity was determined as described previously (Lazar et al., 1995) using
UDP-[14C]glucose purchased from PerkinElmer. C2C12 myotubes
under palmitate-induced insulin-resistant conditions were used for
glycogen synthase activity assay.
Western Blot and Immunoprecipitation
Protein samples were analyzed with antibodies against SIRT1 and
PTP1B (Upstate); InsR, Tyr1146-phosphorylated InsR, Tyr1150/
1151-phosphorylated InsR, phospho-Tyr, Akt, Ser308-phosphory-
lated Akt, Ser473-phosphorylated Akt, and Ser9-phosphorylated
GSK-3b (Cell Signaling); and b-tubulin and actin (Sigma). The immune
complexes were detected using a horseradish peroxidase-conjugated
secondary antibody and visualized with a chemiluminescence reagent
(Pierce). Each blot shown in the figures is representative of at least
three experiments. Protein quantification was performed by Quantity
One software (Bio-Rad), and the intensity values were normalized to
tubulin. Immunoprecipitation of InsR antibody was performed accord-
ing to the manufacturer’s instructions.
RNA Isolation and RT-PCR
Total RNA was prepared from C2C12 cells by TRIzol reagent (Invitro-
gen). cDNAwas then reverse transcribed and amplified by PCR. Quan-
tification was carried out by Quantity One software (Bio-Rad), and the
results were normalized to actin.
Animal Experiments
Animal experiments were performed as described in the Supplemental
Experimental Procedures.
Luciferase Assay
Luciferase reporter constructs were a generous gift from N. Tonks
(Fukada and Tonks, 2001). Luciferase assays were performed in
HEK293T cells in 24-well plate cotransfected with SIRT1 plasmid
(0.6 mg/well), luciferase reporter construct (0.1 mg/well), and pSV40-
b-gal (0.1 mg/well) using Lipofectamine 2000 (Invitrogen). The trans-
fected plasmids were balanced with empty vector. After transfection
for 40 hr, cells were harvested and measured with a luciferase assay
kit (Promega) and normalized to b-galactosidase activity.
Chromatin immunoprecipitation Assay
ChIP was carried out on C2C12 cells using a ChIP Assay Kit (Upstate
Biotechnology).
Statistics
Data are expressed as mean ± SD of at least three independent ex-
periments. Statistical significance was assessed by Student’s t test.
Differences were considered statistically significant at p < 0.05.etabolism 6, 307–319, October 2007 ª2007 Elsevier Inc. 317
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Supplemental Data include Supplemental Experimental Procedures
and three figures and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/6/4/307/DC1/.
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